Hyphens Pharma - 1H26 Earnings Update - Record Margins but Catalysts Still Key for Rerating
We maintain NEUTRAL on Hyphens with a revised target price of S$0.40/share, based on 10.5x FY26E P/E and at a slight discount to the peer average.
95 Views
Hyphens Pharma International Update : Margin Reborn: Quality Over Quantity
We maintain our BUY rating on Hyphens Pharma International Limited ("Hyphens" or "the Group") and revise our 12-month target price to S$0.40 (from...
118 Views
Hyphens Pharma - FY25 Earnings Update - No Clear Catalysts, FY26 Recovery a Low-Bar Normalisation
We remain NEUTRAL on Hyphens Pharma as we think the stock currently trades at fair value, with Vietnam being the primary drag.
162 Views
Primer: Hyphens Pharma International (HYP SP) - Jan 2026
Hyphens Pharma is a specialty pharmaceutical and consumer healthcare group with a strong and growing presence in the ASEAN region, operating...
202 Views
Health Horizons: Singapore's Rising Stars in Biotech & Medtech
Singapore’s healthcare and life sciences sector presents a compelling structural growth opportunity in 2026. In our view, two complementary...
168 Views